Working… Menu
Trial record 77 of 395 for:    CLARITHROMYCIN

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00774644
Recruitment Status : Completed
First Posted : October 17, 2008
Last Update Posted : November 18, 2008
Information provided by:
Ranbaxy Inc.

Brief Summary:
The objective of this study is to compare the relative bioavailability of clarithromycin 500 mg tablets (Ranbaxy Laboratories Limited) with that of BIAXIN® 500 mg tablets in healthy, adult subjects under fasting conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Clarithromycin 500mg Not Applicable

Detailed Description:

The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose, crossover , bioavailability study on clarithromycin formulations comparing clarithromycin 500mg tablets of Ranbaxy Laboratories with Biaxin® tablets 500mg (containing clarithromycin 500 mg)in healthy, adult, human, male subjects under fasting conditions

Eligible subjects underwent pre-study examinations that included a physical examination, 12-lead ECG, and laboratory tests - including hematology, blood chemistries, urinalysis, infectious diseases (Hepatitis B, Hepatitis Ci HIV), and urine drugs of abuse. Laboratory testing for female subjects also included a serum pregnancy test.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Fasting Conditions.
Study Start Date : December 2002
Actual Primary Completion Date : January 2003
Actual Study Completion Date : February 2003

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
Drug: Clarithromycin 500mg
Active Comparator: 2
BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
Drug: Clarithromycin 500mg

Primary Outcome Measures :
  1. Bioequiavlence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Source of Subjects: Non-institutionalized subjects consisting of members of the community at large.
  • Characterization of Study Group:

    1. All subjects selected for this study will be at least 18 years of age.
    2. Female subjects must be unable to become pregnant (postmenopausal for at least 1 year, or surgically sterile).
  • Each subject shall be given a general physical examination within 28 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
  • Each female subject will be given a serum pregnancy test as part of the pre-study screening process.
  • At the end of the study, the subjects will have an exit evaluation consisting of interim history, global evaluation, and clinical laboratory measurements.
  • Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trial for clinical laboratory measurements.
  • Clinical laboratory measurements will include the following:

    • Hematology: hemoglobin, hematocrit,red blood cell count, platelets, and white blood cell count (with differential).

Exclusion Criteria:

  • Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma(during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
  • Subjects whose clinical laboratory test values are greater than 20% outside the normal range may be retested. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
  • Subjects who have a history of allergic responses to the class of drug being tested (including any penicillin product) should be excluded from the study.
  • All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at check-in each study period. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.
  • Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
  • Subjects who have taken any investigational drag within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
  • Female subjects who are pregnant or who are able (women with child bearing potential).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00774644

Layout table for location information
United States, Missouri
Gateway Medical Research Inc.
St.Charles, Missouri, United States, 63301
Sponsors and Collaborators
Ranbaxy Laboratories Limited

Additional Information:
Layout table for additonal information
Responsible Party: Tausif Monif, Ranbaxy Research Laboratories Identifier: NCT00774644     History of Changes
Other Study ID Numbers: B025511
First Posted: October 17, 2008    Key Record Dates
Last Update Posted: November 18, 2008
Last Verified: October 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors